Author:
Chaverra-Muñoz Lillibeth,Briem Theresa,Hüttel Stephan
Abstract
Abstract
Background
The fungal sesquiterpenes Illudin M and S are important base molecules for the development of new anticancer agents due to their strong activity against some resistant tumor cell lines. Due to nonspecific toxicity of the natural compounds, improvement of the pharmacophore is required. A semisynthetic derivative of illudin S (Irofulven) entered phase II clinical trials for the treatment of castration-resistant metastatic prostate cancer. Several semisynthetic illudin M derivatives showed increased in vitro selectivity and improved therapeutic index against certain tumor cell lines, encouraging further investigation. This requires a sustainable supply of the natural compound, which is produced by Basidiomycota of the genus Omphalotus. We aimed to develop a robust biotechnological process to deliver illudin M in quantities sufficient to support medicinal chemistry studies and future preclinical and clinical development. In this study, we report the initial steps towards this goal.
Results
After establishing analytical workflows, different culture media and commercially available Omphalotus strains were screened for the production of illudin M.Omphalotus nidiformis cultivated in a medium containing corn steep solids reached ~ 38 mg L−1 setting the starting point for optimization. Improved seed preparation in combination with a simplified medium (glucose 13.5 g L−1; corn steep solids 7.0 g L− 1; Dox broth modified 35 mL), reduced cultivation time and enhanced titers significantly (~ 400 mg L−1). Based on a reproducible cultivation method, a feeding strategy was developed considering potential biosynthetic bottlenecks. Acetate and glucose were fed at 96 h (8.0 g L−1) and 120 h (6.0 g L−1) respectively, which resulted in final illudin M titer of ~ 940 mg L−1 after eight days. This is a 25 fold increase compared to the initial titer.
Conclusion
After strict standardization of seed-preparation and cultivation parameters, a combination of experimental design, empirical trials and additional supply of limiting biosynthetic precursors, led to a highly reproducible process in shake flasks with high titers of illudin M. These findings are the base for further work towards a scalable biotechnological process for a stable illudin M supply.
Funder
Helmholtz-Zentrum für Infektionsforschung GmbH (HZI)
Publisher
Springer Science and Business Media LLC
Subject
Applied Microbiology and Biotechnology,Bioengineering,Biotechnology
Reference59 articles.
1. Qin H, Xu JW, Xiao JH, Tang YJ, Xiao H, Zhong JJ. Cell factories of higher fungi for useful metabolite production. Adv Biochem Eng Biotechnol. 2016;155:199–235.
2. Karwehl S, Stadler M. Exploitation of fungal biodiversity for discovery of novel antibiotics. Curr Top Microbiol Immunol. 2016. https://doi.org/10.1007/82_2016_496.
3. File TM Jr, Alexander E, Goldberg L, Das AF, Sandrock C, Paukner S, et al. Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community—acquired bacterial pneumonia and common clinical comorbidities. BMC Pulm Med. 2021;21(154):1–10.
4. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83:770–803.
5. Bills GF, Gloer JB. Biologically active secondary metabolites from the fungi. Microbiol Spectr. 2016. https://doi.org/10.1128/microbiolspec.FUNK-0009-2016.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献